Axsome Stock Jumps 14% on FDA Alzheimer's Drug Approval

Axsome Stock Surges on FDA Drug Approval

Axsome Therapeutics, ticker AXSM, saw its shares increase by 14% following the U.S. Food and Drug Administration's approval of its drug, AUVELITY. The approval is for the treatment of agitation associated with dementia due to Alzheimer’s disease.

Situational Overview

This marks the second neuropsychiatric indication for AUVELITY, which is already approved for major depressive disorder in adults. The FDA granted the drug a Breakthrough Therapy designation and conducted a Priority Review. Approval is supported by positive results from the Phase 3 ADVANCE-1 and ACCORD-2 clinical trials, demonstrating a significant improvement in agitation symptoms.

Impact on the Market

The decision positions AUVELITY as a first-in-class treatment for Alzheimer's agitation, a condition affecting up to 76% of patients. With over 7 million Americans diagnosed with Alzheimer's, this approval opens a substantial new market for Axsome. The drug's favorable safety profile, with a low discontinuation rate in trials, further strengthens investor confidence.

Summary and Outlook

This FDA decision is a significant milestone for Axsome Therapeutics, expanding AUVELITY's commercial potential. Market observers will now monitor the drug's launch and adoption rates. The company is scheduled to host a webcast to discuss the development further.

FAQ

Q: What is AUVELITY now approved to treat?
A: AUVELITY is approved for treating agitation in Alzheimer's patients and for major depressive disorder in adults.

Q: Why did Axsome Therapeutics' stock price increase?
A: The stock rose due to the FDA's approval, which allows the company to market its drug to a large new patient population, signaling significant revenue potential.

Source: Investing.com